A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.

person Nehal J. Lakhani START Midwest, Grand Rapids, MI info_outline Nehal J. Lakhani, Omid Hamid, Irene Brana, M. Julia Lostes-Bardaji, Pablo Gajate, Maria Pilar Lopez-Criado, Paul Swiecicki, Maria J. de Miguel, Marta Gil-Martin, Victor Moreno, Aixa Elena Soyano Muller, Ana Gonzalez Ortiz, Dylan Sun, Dimple Modi, Wenjun Zheng, Vladimir Jankovic, Mark Salvati, Matthew G. Fury, Mihaela C. Cristea

Authors person Nehal J. Lakhani START Midwest, Grand Rapids, MI info_outline Nehal J. Lakhani, Omid Hamid, Irene Brana, M. Julia Lostes-Bardaji, Pablo Gajate, Maria Pilar Lopez-Criado, Paul Swiecicki, Maria J. de Miguel, Marta Gil-Martin, Victor Moreno, Aixa Elena Soyano Muller, Ana Gonzalez Ortiz, Dylan Sun, Dimple Modi, Wenjun Zheng, Vladimir Jankovic, Mark Salvati, Matthew G. Fury, Mihaela C. Cristea Organizations START Midwest, Grand Rapids, MI, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Ramón y Cajal University Hospital, Madrid, Spain, The University of Texas MD Anderson Cancer Center, Madrid, Spain, University of Michigan, Ann Arbor, MI, START Madrid - CIOCC, Madrid, Spain, Institut Català d’Oncologia-IDIBELL, L’Hospitalet-Barcelona, Barcelona, Spain, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, Regeneron Pharmaceutials, Inc., Tarrytown, NY Abstract Disclosures Research Funding Regeneron Pharmaceuticals, Inc. Background: REGN6569 is a fully human immunoglobulin G1 monoclonal antibody (mAb) that is highly specific for glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR). GITR is expressed on several immune cell subtypes, notably regulatory T cells (Tregs), and activated natural killer (NK) cells. REGN6569 demonstrated greater in vitro antibody-dependent cell-mediated cytotoxicity against GITR-expressing Tregs, as compared to GITR-expressing CD8+ T cells. Mouse studies showed that REGN6569 + cemiplimab (anti-PD-1) combination treatment achieved longer-term tumor responses compared with either drug alone. Methods: This is a first-in-human study (NCT04465487) evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of REGN6569 administered intravenously (IV) every 3 weeks (Q3W) + cemiplimab 350 mg IV Q3W, in pts with advanced solid tumors for which immune checkpoint inhibitor therapies have not been approved or are not available. The study includes a dose-escalation part with 5 dose levels (DL1-DL5) for REGN6569 (“4+3” design), with an initial dose of REGN6569 monotherapy given as a safety lead-in followed by REGN6569 + cemiplimab in subsequent doses. Results: As of the data cutoff date Oct 20, 2023, the dose-escalation part has been completed. 29 pts (median age 58.0 years, 62.1% male) were treated with REGN6569 + cemiplimab, up to the 1200 mg dose level (DL5), across many solid tumor types. The most common tumor type was colorectal cancer (34.5%). One pt (40 mg DL2) experienced a dose-limiting toxicity (Grade 3 hepatic failure); maximum tolerated dose was not reached. Twelve pts (41.4%) had a Grade ≥3 treatment-emergent adverse event (TEAE) and 16 pts (55.2%) had a treatment-related TEAE (any grade). The most frequent TEAEs (any grade) were arthralgia (24.1%), infusion-related reactions, and abdominal pain (20.7% each). There were no treatment-related deaths; 19 (65.5%) pts had disease progression leading to death. Two pts achieved ongoing partial responses by investigator assessment with REGN6569 + cemiplimab treatment: 1 pt with mucoepidermoid tumor of the parotid gland treated with 120 mg (DL3) REGN6569 and 1 pt with B3 thymoma treated with 400 mg (DL4) REGN6569, with duration of responses, 5.6 and 10.4 months, respectively. Full receptor occupancy on circulating Tregs was observed in all dose cohorts following REGN6569 treatment. Increased frequency (~10–50%) of proliferating NK cells in peripheral blood was observed post REGN6569 treatment across all dose cohorts. Conclusions: In this dose-escalation study, REGN6569 was administered up to 1200 mg (DL5) in combination with cemiplimab with one dose-limiting toxicity. The study has progressed to dose-expansion cohorts in anti–PD-1-resistant head and neck cancer, with pts treated with REGN6569 (DL5) + cemiplimab. Clinical trial information: NCT04465487.

Clinical